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| INTRODUCTION
The direct oral anticoagulant (DOAC) dabigatran is a direct thrombin inhibitor. Dabigatran etexilate (DE), the prodrug of dabigatran, is approved for prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and secondary prevention of venous thromboembolism. In clinical trials and real-world observational studies, dabigatran was at least as effective as warfarin, with a favorable bleeding profile. [1] [2] [3] [4] [5] A sub-analysis in Japanese patients from the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial indicated similar safety and efficacy for DE vs warfarin and higher bleeding rates for warfarin in Asians vs non-Asians 6, 7 ; this was attributed to postulated genetic differences in blood coagulation between Asian and non-Asian subjects. The reductions in hemorrhagic stroke and major bleeding rates were comparable between Asians vs non-Asian patients treated with DE. 8 Nevertheless, all anticoagulants are associated with risk of severe bleeding. [9] [10] [11] [12] Owing to the relatively short half-life of dabigatran (12-14 hour), 13 cessation of treatment and standard supportive care (eg, volume replacement) can be used to manage bleeding in many patients with adequate renal function, but this may be inadequate in emergency situations. [13] [14] [15] [16] Consequently, there has been a demand for rapid, specific reversal agents for use in cases of rare severe bleeding or when urgent surgery or interventions are needed. One such reversal agent is idarucizumab, a humanized monoclonal antibody fragment, which binds dabigatran with high affinity and specificity. 17 A phase I study of idarucizumab in healthy, predominantly
Caucasian, male volunteers demonstrated that peak plasma exposure of idarucizumab was achieved at, or shortly after a 5-minute intravenous infusion; this was followed by rapid elimination within 24 hour. 18 Idarucizumab treatment in Caucasian volunteers receiving dabigatran led to immediate, complete, and sustained reversal of anticoagulation and was well tolerated. 19 In an interim analysis of a phase III trial in dabigatran-treated patients with severe bleeding or in need of an urgent surgery/procedure, idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. 17 Safety and efficacy data in Asians are limited.
The present phase I study in healthy Japanese male volunteers was designed to confirm the safety, tolerability, and pharmacokinetics of idarucizumab alone and with dabigatran at steady state, and to explore the effect of ascending doses of idarucizumab on the pharmacokinetics of dabigatran and the reversal of dabigatran anticoagulant activity (pharmacodynamics).
| MATERIALS AND METHODS

| Study design
This randomized, double-blind (within dose groups), placebocontrolled, single-center trial was conducted at Medical Co. LTA Sumida Hospital, Tokyo, Japan (January-August 2014). It comprised two parts; in both parts, male subjects were randomized in a 3:1 ratio, idarucizumab to placebo. (ClinicalTrials.gov registration no. Idarucizumab doses were selected based on the phase I trial of healthy Caucasian male volunteers. 18, 19 In both parts of the present study, idarucizumab was started at a dose of 1 g as a safety precaution. The next dose level was administered after evaluation of the safety data covering at least a 21-hour period. Subjects (males) remained on site for at least 72 hour following drug administration at each dose level. To allow for monitoring of the effects of the highest dose of idarucizumab (8 g), the active drug, or its placebo, was administered first in two subjects, then in a further two, followed by the remaining four. Both the subject and investigator were blinded to treatment with the study drug or placebo, although the current dose level was known.
A dosing schedule of DE 220 mg bid for the first 3 days and once daily on day 4 in a fasting state was selected to investigate safety.
The same dosing schedule for DE was repeated on day 8 and ended on day 11 to examine the efficacy of idarucizumab to reverse the
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Essentials
• Idarucizumab, a monoclonal antibody fragment, binds dabigatran with high affinity and specificity.
• In this phase 1 trial, healthy Japanese males received idarucizumab alone or with dabigatran.
• Idarucizumab achieved immediate, complete and sustained reversal of dabigatran anticoagulation.
• Idarucizumab was well tolerated and demonstrated no pro-coagulant effects.
F I G U R E 1 Study design. (A) Part 1. Subjects received either placebo (n=2/dose group) or single intravenous doses of idarucizumab, 1, 2, or 4 g as a 5-minute infusion or 8 g as a 1-hour infusion (n=6/group). ADA=antidrug antibody. *21-hour interval between dose levels. † Dose as a 5-minute infusion. ‡ Dose as a 1-hour infusion. (B) Part 2. Subjects received oral DE for 4 days (220 mg bid: days 1, 2, and 3; 220 mg: the morning of day 4) followed by a 3-day wash-out period. DE was readministered on days 8, 9, and 10 at 220 mg bid, with a morning 220-mg dose on day 11. On day 11, idarucizumab doses of 1, 2, or 4 g were administered as 5-minute intravenous infusions ~2 hour after the last dabigatran dose corresponding to the timing around the maximum plasma concentration (C max ) of dabigatran; 5 g was administered as two 5-minute infusions of 2.5 g separated by a 15-minute interval. In each 12-person dose group, 3 subjects were randomized to placebo and 9 to idarucizumab. ADA, antidrug antibody; bid, twice daily; DE, dabigatran etexilate; qd, once daily. *21-hour interval between dose levels. † Dose as a 5-minute infusion. ‡ Dose as two 5-minute infusions separated by 15 minute anticoagulant activity of DE. This dose of DE was selected to cover peak plasma concentration levels in the RE-LY trial where plasma concentration around 2-hour post-dose achieved was 184 ng/mL 20 and corresponded with the dosing schedule of the phase I trial in Caucasian subjects (males) 19 (NCT identifier, NCT01688830). At this dosage, the C max of dabigatran at steady state covers the C max of dabigatran after administration of 150 mg bid to the patient population in the phase III global study conducted in patients with nonvalvular atrial fibrillation including Japanese individuals (unpublished data).
| Study subjects and conduct
This two-part study randomized 80 healthy male Japanese volunteers aged ≥20 and ≤45 years (body mass index ≥18.5 and <25.0 kg/m 2 ).
Exclusion criteria included any abnormal findings at the screening examination; clinically relevant comorbidities including gastrointestinal, hepatic, renal, cardiovascular, metabolic, central nervous system, immunological or hormonal disorder; history or evidence of a blood disorder; and subjects unable to refrain from smoking during hospitalization (or a current smoker >10 cigarettes/day or equivalent).
The study protocol was approved by an institutional review board.
The trial was reported in line with CONSORT guidelines and conducted according to the Declaration of Helsinki, the International Conference on Harmonization good clinical practice (GCP), and relevant regulatory and GCP requirements. All subjects provided written informed consent.
The randomization list was generated using a validated pseudorandom number generator and a supplied seed number to create reproducible and nonpredictable allocation.
| Antidrug antibody analysis
For the analysis of anti-idarucizumab antibodies (ADAs), samples were collected at baseline, end of study (EOS), and 4-week and 3-month follow-ups. ADAs were detected in human plasma samples by a validated bridging electrochemiluminescence method (Covance Laboratories Inc., Chantilly, VA, USA). Positive samples were subjected to a confirmatory assay and additional analyses. ADAs were classified as pre-existing (present in the baseline sample before study drug administration) or treatment-emergent (present/raised after idarucizumab administration).
ADA titer was determined as the highest dilution factor at which the mean signal for the sample remains above or at the assay cut-point level. The titer is expressed as the dilution factor. For example, for a sample that was positive with a 40-fold dilution but negative with an 80-fold dilution, the assigned titer would be 40. The assay did not have an initial minimum required dilution. Therefore, a titer of 1 is assigned to a sample that was positive only when assayed undiluted.
| Pharmacokinetic/pharmacodynamic analyses
Pharmacokinetic and pharmacodynamic analyses were performed using validated assay methods. 21, 22 The detailed methods of analyses are provided in the supplementary material.
| Outcomes
| Safety outcomes
The primary safety endpoint was the number (%) of subjects with adverse events (AEs) assessed by the investigator to be drug-related.
Safety outcomes included AEs, laboratory tests (including hematology,
clinical chemistry, urine analysis, coagulation parameters and antidrug antibodies), electrocardiogram (ECG), vital signs and local tolerability.
| Pharmacokinetic parameters
Pharmacokinetic parameters in part 1 were: idarucizumab C max , area under the curve (AUC 0-∞ ), and excretion after 72 hour (Ae 0-72 ; Ae 0-73 for the 8-g group). In part 2, these were: idarucizumab C max , AUC 0-∞ , Ae 0-72 , total dabigatran Ae 0-74 and unbound dabigatran AUC 2-12 on days 4 and 11.
| Pharmacodynamic parameters
The secondary pharmacodynamic endpoint in study part 2 was: area under the effect curve between 2 and 12 hour on days 4 and 11 for dTT. Additional clotting tests (ECT, TT, aPTT) were included. 
| Statistical analyses
The planned sample size (n=80) was based on previous phase I trials of idarucizumab. A group size between 8 and 12 per dose level is commonly used in healthy subject trials and was considered sufficient for exploratory investigation of single/multiple dose safety and pharmacokinetics. 23 Descriptive statistics for safety, pharmacokinetic, and pharmacodynamic endpoints were calculated. Dose proportionality of idarucizumab was assessed using a regression model with 95% confidence interval for the slope.
All parameters are presented using descriptive statistics; no formal statistical tests were undertaken.
| RESULTS
| Subjects
In total, 81 males were enrolled in the study; 80 were randomized to part 1 (n=32) or part 2 (n=48) ( Figure 2 ). All subjects in part 1 and all randomized subjects from part 2 (one subject was withdrawn before randomization because of AEs [bruising of the leg, hemorrhage and swelling] after receiving dabigatran) completed the study ( Figure 2 ).
Demographic characteristics were similar between idarucizumab and placebo groups (Table 1) . 
| Safety outcomes
AEs
In part 1, one of six (16.7%) subjects receiving placebo (5-minute infusion) had an elevated blood creatine phosphokinase level, which was mild and assessed as drug-related by the investigator; no AEs were reported (drug-related or otherwise) in remaining subjects. There were no AEs reported in part 2. Thus, in both parts of the study, there were no severe or serious AEs in randomized patients. Additionally, no clinically significant changes were seen in other laboratory and safety parameters, including 12-lead ECG, vital signs and local infusion tolerability.
ADA pooled analysis
Of the 80 subjects in both study parts, 14 (17.5%) were positive for pre-existing ADA, with positive titers ranging from 1 to 20. For 12 of these subjects (four placebo, eight idarucizumab), titers of pre-existing ADA were relatively constant throughout the study.
Six of 60 (10%) idarucizumab-treated subjects developed treatment-emergent ADAs with positive titers ranging from 1 to 40, the latter value being reported in one subject. Two subjects had pre-existing ADAs, and their ADA titers increased at follow-up visits at 4 weeks and 3 months. Four subjects had no detectable ADA at baseline, but positive ADA titers were recorded at follow-up visits. Of of idarucizumab 1-4 g. For C max , the 8-g dose group was excluded due to the different infusion time. Inter-individual variability was low.
The geometric mean (gMean) initial half-life (t 1/2, 2 ) and gMean terminal elimination half-life of idarucizumab, administered with or without dabigatran, were 0.52-1.04 hour and 6.0-10.3 hour, respectively, and were independent of dose. Volume of distribution of idarucizumab, administered with or without dabigatran, was ~5.5-7.5 L, and total plasma clearance was ~36-41 mL/min, both being relatively constant across the dose range. Urinary excretion and CL R of idarucizumab at 1-4-g doses in the presence of dabigatran at steady state were approximately two to three times higher than without dabigatran, but were comparable at 5-and 8-g doses.
Dabigatran pharmacokinetics
The plasma concentration-time profile of active dabigatran alone was as expected 13 ( Figure 4A ). Plasma concentrations of unbound dabigatran ( Figure 4B ) and active dabigatran decreased to below the limit of quantification (BLQ) or close to BLQ immediately post-idarucizumab. respectively. At the 4-g dose of idarucizumab, unbound dabigatran was measurable only from 24 to 72 hour and 24 to 48 hour at low levels below 4 ng/mL. In the 2×2.5-g idarucizumab dose group, measurable levels of unbound dabigatran were present only after 48 hour, much later than the timeframes at the lower doses ( Figure 4B ).
| Pharmacodynamic effects on coagulation parameters
Idarucizumab alone
In subjects receiving idarucizumab alone, no differences were observed in coagulation parameters (dTT, ECT, TT, aPTT) between pre-and post-dose measurements, regardless of idarucizumab dose.
Idarucizumab had no apparent effect on endogenous thrombin formation, as measured by CAT.
Idarucizumab reversal of dabigatran-induced anticoagulation
On day 4, administration of DE resulted in prolongation of clotting times, as expected (data not shown). Idarucizumab 1, 2, 4, or 2.5+2.5 g resulted in immediate and complete reversal of anticoagulant effect,
shown by mean dTT falling to below the ULN; the reversal effect was not observed after placebo ( Figure 5A and B). Mean dTT remained below the ULN during the observed period for up to 72 hour after administration of idarucizumab 4 g ( Figure 5A ) and 2.5+2.5 g ( Figure 5B ). At lower doses, mean coagulation times showed a partial return of the anticoagulant effect of dabigatran after 1-2 hour 25  240  242  244  246  248  250  252  254  256  258 266 290 314   140   120   80   100   60   20   40   0  240  242  244  246  248  250  252  254  256  258 266 290 314   85   75   65   55   45   35   25  240  242  244  246  248  250  252  254  256  258 266 290 314   240   200   160   120   80   40   0  240  242  244  246  248  250  252  254  256  258 266 290 showed similar profiles to dTT post-idarucizumab.
As expected, thrombin generation and derived parameters were raised after the last dose of dabigatran. In particular, the thrombin lag time ratio and thrombin time-to-peak ratio increased approximately 5-and 2.5-fold, respectively. The ratio of baseline values to postidarucizumab thrombin generation parameter values demonstrated an increase relative to baseline; post-idarucizumab (2-5 g) and were close to 1. Changes in thrombin lag time ratio and thrombin time to peak ratio were most pronounced (Table 3) .
| DISCUSSION
In this phase I study the safety and pharmacokinetics of idarucizumab were investigated in healthy Japanese males for the first time.
Administration of idarucizumab at doses of 4 and 2.5+2.5 g led to immediate, complete, and sustained reversal of dabigatran-induced anticoagulation for the duration of the observation period (up to 72 hour); at 1 and 2 g doses of idarucizumab, a partial return of the anticoagulant effect of dabigatran was observed (1-2 hour after idarucizumab administration); idarucizumab was safe and well tolerated at all doses. These findings support results obtained in a largely Caucasian population.
18,19
| Safety profile
There were no unexpected or clinically relevant safety concerns reported and no AEs considered by the investigators to be related to
idarucizumab.
An increase in prothrombotic effect is a potential risk following reversal of anticoagulation; a meta-analysis of trials in vitamin K antagonist-treated patients receiving prothrombin complex concentrates for anticoagulation reversal suggested a low but quantifiable risk of thromboembolism. 15 It could not be determined whether this represents underlying risk or is a prothrombotic effect. Despite being structurally similar to thrombin, idarucizumab has not exhibited specific thrombin-like enzymatic activity 24 ; in in vitro studies, idarucizumab showed no binding to known thrombin substrates and had no activity in coagulation or platelet aggregation tests. 24, 25 Idarucizumab demonstrated no prothrombotic effects, alone or during reversal of dabigatran anticoagulation, as assessed by endogenous thrombin generation parameters. These parameters were not affected by idarucizumab alone and returned to baseline values (but not beyond) during reversal. Idarucizumab administered alone at doses up to 8 g demonstrated no effect on coagulation (assessed by dTT, ECT, aPTT, or TT) in these healthy Japanese volunteers. These findings are consistent with preclinical and clinical studies showing no prothrombotic effect resulting from idarucizumab use.
19-21
As a specific humanized Fab given as a single intravenous dose, idarucizumab has low potential for immunogenic reactions. Treatmentemergent ADAs were found in 6 of 60 subjects who received idarucizumab (in 2 of these males, ADAs were pre-existing but increased after treatment), 4 of which were possibly persistent and 2 transient. These primary, treatment-emergent ADA responses do not occur until after idarucizumab has been completely cleared. Any effect of treatmentemergent ADA on idarucizumab PK/PD could only occur if high titer ADA are present at the time of a subsequent dose of idarucizumab. It has been estimated that at the highest titer observed in the present study, a titer of 40, the amount of ADA circulating is equivalent (on a molar basis) to <0.1% of a 5 g dose of idarucizumab. 26 It is likely that T A B L E 3 Ratios of thrombin generation parameters relative to baseline, 2.5 h after the last dose of dabigatran etexilate (0.5 h after idarucizumab or placebo, if administered) the ADA titer would need to be many times higher than 40 to have an effect on PK/PD of a subsequent dose of idarucizumab. In a pooled analysis of phase I studies, no AEs were indicative of immunogenic reactions, and the pharmacokinetics and pharmacodynamics of idarucizumab were unaffected. 26 The safety profile of idarucizumab in Japanese male subjects was comparable to that in phase I studies in which the majority of volunteers were healthy Caucasians; idarucizumab was well tolerated. The proportion of subjects with pre-existing antibodies that were crossreactive with idarucizumab was also similar.
| Pharmacokinetic and pharmacodynamic profiles
The pharmacokinetic profile of idarucizumab displayed plasma con- The urinary excretion and CL R of idarucizumab with dabigatran were approximately two to three times higher than with idarucizumab alone. This was not due to adsorption to container, because the assay remained accurate after several dilutions, proven by the bioanalytical validation study.
The reversal of anticoagulant effects verified by the disappearance of unbound dabigatran was sustained at doses of 4 and 2.5+2.5 g and was consistent with the total body load of dabigatran and the 1:1 stoichiometry of the binding properties of idarucizumab to dabigatran. 24 At the 220 mg bid dose the median steady state C max on day 4 was 286 ng/mL for total dabigatran, with 10-90th percentiles of 136-432 ng/mL. The steady state C max at the 90th percentile was comparable to the dabigatran exposure at 2 hour post-dose steady state plasma concentration at the 90th percentile (383 ng/ mL, 150 mg bid) as observed in the RE-LY study. 20 The increase in plasma concentrations of total dabigatran observed immediately after idarucizumab administration reflected redistribution of dabigatran from the peripheral compartment and bound to idarucizumab in the central compartment. This bound dabigatran was inactive dabigatran;
there was no measurable anticoagulant activity. Idarucizumab binds to and inactivates dabigatran in the central compartment, which approximated the central compartment plus interstitial space. This binding reduces the unbound dabigatran centrally and, in a dynamic equilibrium, dabigatran in the peripheral tissues moves into the central compartment. If unbound idarucizumab remains, this redistributed dabigatran is inactivated by idarucizumab. 22 If there is no free idarucizumab remaining, the coagulation parameters re-elevate. The sustained effect corresponds to the almost irreversible binding shown in preclinical studies. 24 The slow off-rate of idarucizumab binding to dabigatran 24 means that dabigatran remains bound to idarucizumab until the complex is eliminated from the body through a combination of renal catabolism and, for doses ≥1 g, urinary excretion. 19 Lower doses of idarucizumab (1 and 2 g) were associated with a partial return of anticoagulant effect, reflecting redistribution of unbound dabigatran that was not bound by idarucizumab, since there was no remaining free idarucizumab. 19 The pharmacokinetic profile of idarucizumab in Japanese male subjects was comparable to results from phase I studies with predominantly healthy Caucasian males; differences in exposure were negligible after weight normalization, since mean body weight was lower in Japanese subjects. Mean body weight values in Caucasian subjects were ~80 kg for both study parts, and in Japanese male subjects were ~65 kg in part 1 and 61 kg in part 2. Since exposure to dabigatran is higher in Japanese subjects (AUC 2-12,ss 1480 ng/mL, n=48, geometric coefficient of variation [gCV]=44.1%) than in Caucasians (1090 ng/ mL, n=35, gCV=56.4%), a 4-g idarucizumab dose was needed for sustained reversal, compared with the 2-g idarucizumab dose that was sufficient for sustained reversal in Caucasians. 
| Study strengths and limitations
Although double-blind conditions were maintained within each dose group, investigators and subjects knew the current dose level due to the risk-minimizing sequential dose escalation scheme. Measurement of objective parameters of coagulation limited the potential for bias this could have introduced. The present study did not include women.
However, the pharmacokinetic profiles of idarucizumab were similar in males and females (data not shown). 28 The safety profile of idarucizumab in healthy volunteers may differ from that in the target patient population, who are much older and likely to have life-threatening underlying conditions and multiple comorbidities. This could result in different responses to treatment. Interim data from bleeding patients or patients requiring emergency surgery have not identified any safety concerns. The rapid, complete and sustained reversal of anticoagulant effects in patients with a 5-g dose was similar to that seen in healthy subjects. 29 The effect of idarucizumab on bleeding was not determined in this study, although reversal of anticoagulation was demonstrably effective through measurement of objective parameters. This is the only trial in healthy volunteers to include idarucizumab at the 2.5+2.5 g dose with 15-minute intervals between infusions; this dose was investigated in the phase III Reversal of Dabigatran Anticoagulant Effect With Idarucizumab (RE-VERSE AD) trial. 29 
| CONCLUSIONS
In this first study of idarucizumab in a healthy Japanese male population, both regimens of idarucizumab administration (4 and 2.5+2. 
